POGGESI, ITALO
 Distribuzione geografica
Continente #
EU - Europa 776
NA - Nord America 434
AS - Asia 210
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.425
Nazione #
NL - Olanda 473
US - Stati Uniti d'America 430
CN - Cina 191
IE - Irlanda 140
FI - Finlandia 34
IT - Italia 33
DE - Germania 32
UA - Ucraina 31
SG - Singapore 16
SE - Svezia 13
GB - Regno Unito 7
CA - Canada 4
AU - Australia 3
BE - Belgio 3
PL - Polonia 3
RU - Federazione Russa 3
PT - Portogallo 2
CZ - Repubblica Ceca 1
EU - Europa 1
FR - Francia 1
KG - Kirghizistan 1
KR - Corea 1
NZ - Nuova Zelanda 1
TR - Turchia 1
Totale 1.425
Città #
Dublin 140
Chandler 100
Jacksonville 49
Nanjing 44
Beijing 29
Boardman 23
Princeton 20
Wilmington 19
Ashburn 18
Hebei 17
Helsinki 17
Lawrence 17
Nanchang 17
Medford 16
Dearborn 15
Jiaxing 15
Shanghai 15
Changsha 14
Ann Arbor 12
Shenyang 12
Singapore 12
Tianjin 8
Hangzhou 7
Los Angeles 6
Milan 5
Cagliari 4
Chicago 4
Dallas 4
Houston 4
Pavia 4
Piscataway 4
Seattle 4
Toronto 4
Woodbridge 4
Brussels 3
Krakow 3
Saint Petersburg 3
Zhengzhou 3
Coimbra 2
Garching 2
Norwalk 2
Perth 2
San Francisco 2
Taizhou 2
Auckland 1
Augusta 1
Bishkek 1
Brno 1
Carate Brianza 1
Changchun 1
Des Moines 1
Dolo 1
Fairfield 1
Henderson 1
Kunming 1
Lurate Caccivio 1
Lynnwood 1
Melbourne 1
Ningbo 1
Oklahoma City 1
Olgiate Olona 1
Origgio 1
Paris 1
Rivarolo Canavese 1
Seocho-gu 1
Seregno 1
Sunnyvale 1
Vaiano Cremasco 1
Verona 1
Weil am Rhein 1
Totale 733
Nome #
Steady-state equivalence of drug- and biomarker driven models in tumor growth experiments 537
Tumor-growth inhibition in preclinical animal studies: steady-state analysis of biomarker-driven models 90
Biomarker-driven models of tumor growth inhibition in preclinical animal studies 79
Tumor growth modelling for drug development 71
Integration of response, tolerability and dropout in flexible-dose trials: a case study in depression 69
Predictive assessments of pharmacokinetic alterations in subjects with renal disease 61
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies 55
Method to evaluate the systemic exposure in toxicological and pharmacological studies 54
Mathematical modeling of efficacy and safety for anticancer drugs clinical development 50
Use of Physiology-Based Elements to Predict the Pharmacokineticsof New Drugs 49
Current mathematical models for cancer drug discovery 46
Prediction of the Effect of Renal Impairment on the Pharmacokinetics of New Drugs 45
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis 45
Pharmacokinetic-Pharmacodynamic Modeling in Drug Development with Special Reference to Oncology 43
A Population Pharmacokinetic Model of Macitentan and Its Active Metabolite Aprocitentan in Healthy Volunteers and Patients with Pulmonary Arterial Hypertension 43
Modeling approaches for reducing safety-related attrition in drug discovery and development: a review on myelotoxicity, immunotoxicity, cardiovascular toxicity, and liver toxicity 34
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib 33
Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis 28
Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial 26
Totale 1.458
Categoria #
all - tutte 4.614
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.614


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202069 0 0 0 7 0 12 5 10 1 13 21 0
2020/202168 7 5 2 7 1 8 0 13 4 10 9 2
2021/2022562 1 1 4 0 1 2 0 18 1 0 16 518
2022/2023340 40 27 10 12 25 25 1 19 161 3 7 10
2023/2024129 32 20 0 12 8 17 9 15 2 4 6 4
2024/202541 8 24 6 3 0 0 0 0 0 0 0 0
Totale 1.458